Patents by Inventor Kirk P. Conrad
Kirk P. Conrad has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10493131Abstract: The subject invention provides methods for recruitment of bone marrow-derived cells, including bone marrow-derived endothelial cells (BMDEC), and increasing their function by administration of relaxin. The methods of the invention can be used in, for example, treating conditions amenable to treatment by recruitment of bone marrow-derived cells, such as BMDEC and bone marrow-derived angio-osteogcnic progenitor cell.Type: GrantFiled: August 30, 2012Date of Patent: December 3, 2019Assignee: University of Florida Research Foundation, IncorporatedInventors: Kirk P. Conrad, Mark S. Segal
-
Patent number: 10434146Abstract: The subject invention relates to methods for improving a subject's vasculature to normalize maternal hemodynamics, particularly in subjects attempting to conceive via assisted reproductive technologies, and comprises increasing relaxin levels in a subject or increasing any one or more of: relaxin synthesis, relaxin receptor synthesis, relaxin binding to the relaxin receptor, or relaxin receptor activity.Type: GrantFiled: June 2, 2016Date of Patent: October 8, 2019Assignee: University of Florida Research Foundation, Inc.Inventor: Kirk P. Conrad
-
Patent number: 9907833Abstract: The subject application relates to methods for treating a placental syndrome, wherein relaxin is administered during the late secretory/luteal (LS) phase of the menstrual cycle in women who have a propensity for developing the placental syndrome. In certain embodiments, administration of relaxin continues beyond the LS phase and into pregnancy.Type: GrantFiled: July 25, 2014Date of Patent: March 6, 2018Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATEDInventor: Kirk P. Conrad
-
Publication number: 20160271223Abstract: The subject invention relates to methods for improving a subject's vasculature to normalize maternal hemodynamics, particularly in subjects attempting to conceive via assisted reproductive technologies, and comprises increasing relaxin levels in a subject or increasing any one or more of: relaxin synthesis, relaxin receptor synthesis, relaxin binding to the relaxin receptor, or relaxin receptor activity.Type: ApplicationFiled: June 2, 2016Publication date: September 22, 2016Inventor: Kirk P. CONRAD
-
Patent number: 9381231Abstract: The subject invention relates to methods for improving a subject's vasculature to normalize maternal hemodynamics, particularly in subjects attempting to conceive via assisted reproductive technologies, and comprises increasing relaxin levels in a subject or increasing any one or more of: relaxin synthesis, relaxin receptor synthesis, relaxin binding to the relaxin receptor, or relaxin receptor activity.Type: GrantFiled: October 9, 2013Date of Patent: July 5, 2016Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventor: Kirk P. Conrad
-
Publication number: 20150031616Abstract: The subject application relates to methods for treating a placental syndrome, wherein relaxin is administered during the late secretory/luteal (LS) phase of the menstrual cycle in women who have a propensity for developing the placental syndrome. In certain embodiments, administration of relaxin continues beyond the LS phase and into pregnancy.Type: ApplicationFiled: July 25, 2014Publication date: January 29, 2015Inventor: KIRK P. CONRAD
-
Publication number: 20140242074Abstract: The subject invention provides methods for recruitment of bone marrow-derived cells, including bone marrow-derived endothelial cells (BMDEC), and increasing their function by administration of relaxin. The methods of the invention can be used in, for example, treating 5 conditions amenable to treatment by recruitment of bone marrow-derived cells, such as BMDEC and bone marrow-derived angio-osteogcnic progenitor cell.Type: ApplicationFiled: August 30, 2012Publication date: August 28, 2014Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventors: Kirk P. Conrad, Mark S. Segal
-
Publication number: 20140100159Abstract: The subject invention relates to methods for improving a subject's vasculature to normalize maternal hemodynamics, particularly in subjects attempting to conceive via assisted reproductive technologies, and comprises increasing relaxin levels in a subject or increasing any one or more of: relaxin synthesis, relaxin receptor synthesis, relaxin binding to the relaxin receptor, or relaxin receptor activity.Type: ApplicationFiled: October 9, 2013Publication date: April 10, 2014Applicant: University Of Florida Research Foundation, Inc.Inventor: KIRK P. CONRAD
-
Publication number: 20140057832Abstract: The present invention provides methods for increasing arterial compliance. The methods generally involve administering to an individual in need thereof an effective amount of relaxin. The present invention further provides methods of increasing arterial compliance in individuals who have Type 1 or Type 2 diabetes. The present invention further provides methods of increasing arterial compliance in perimenopausal, menopausal, and post-menopausal women. The present invention further provides methods of increasing arterial compliance in individuals who have or who are at risk of developing age-associated arterial stiffness.Type: ApplicationFiled: November 5, 2013Publication date: February 27, 2014Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Kirk P. Conrad, Sanjeev G. Shroff
-
Patent number: 8602998Abstract: The present invention provides methods for increasing arterial compliance. The methods generally involve administering to an individual in need thereof an effective amount of relaxin. The present invention further provides methods of increasing arterial compliance in individuals who have Type 1 or Type 2 diabetes. The present invention further provides methods of increasing arterial compliance in perimenopausal, menopausal, and post-menopausal women. The present invention further provides methods of increasing arterial compliance in individuals who have or who are at risk of developing age-associated arterial stiffness.Type: GrantFiled: January 6, 2011Date of Patent: December 10, 2013Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Kirk P Conrad, Sanjeev G Shroff
-
Publication number: 20130303455Abstract: The present disclosure relates to methods for assessing increased risk of preeclampsia in a pregnant woman. The methods described herein employ measuring relaxin levels, and optionally measuring C-reactive protein levels in a biological sample of a pregnant woman. The disclosure further encompasses methods of reducing risk of preeclampsia through administration of a pharmaceutical formulation of relaxin to a pregnant woman.Type: ApplicationFiled: July 12, 2013Publication date: November 14, 2013Inventors: Dennis Stewart, Kirk P. Conrad, Arundhathi Jeyabalan, Marion Dahike
-
Patent number: 8574851Abstract: The present disclosure relates to methods for detecting an increased risk of preeclampsia, determining the presence of preeclampsia, reducing the likelihood that preeclampsia will develop and treating preeclampsia. It also provides methods of measuring relaxin levels in a biological sample of a pregnant woman.Type: GrantFiled: November 24, 2009Date of Patent: November 5, 2013Assignees: Corthera, Inc., University of Pittsburgh-Of the Commonwealth System of Higher Education, University of Florida Research Foundation, Inc.Inventors: Dennis Stewart, Kirk P. Conrad, Arundhathi Jeyabalan
-
Publication number: 20130012441Abstract: The present disclosure relates to methods for assessing increased risk of preeclampsia in a pregnant woman. The methods described herein employ measuring relaxin levels, and optionally measuring C-reactive protein levels in a biological sample of a pregnant woman. The disclosure further encompasses methods of reducing the risk of preeclampsia and treating it, once it has occurred by administering a pharmaceutical formulation of relaxin to a pregnant woman.Type: ApplicationFiled: February 16, 2012Publication date: January 10, 2013Inventors: Dennis Stewart, Kirk P. Conrad, Arundhathi Jeyabalan, Marion Dahike
-
Publication number: 20110281801Abstract: The present disclosure relates to methods for detecting an increased risk of preeclampsia, determining the presence of preeclampsia, reducing the likelihood that preeclampsia will develop and treating preeclampsia. It also provides methods of measuring relaxin levels in a biological sample of a pregnant woman.Type: ApplicationFiled: November 24, 2009Publication date: November 17, 2011Applicant: University of Pittsburgh-Of the Comonwealth SystemInventors: Dennis Stewart, Kirk P. Conrad, Arundhathi Jeyabalan
-
Publication number: 20110171650Abstract: Gene expression patterns contemporaneous with early placental development in the first trimester of preeclamptic versus unaffected pregnancies have been obtained. Observation of differences in these gene expression patterns has allowed the identification of biomarkers that are useful in predicting and monitoring preeclampsia. These biomarkers are also useful in screening potential therapeutics for efficacy in the prevention or treatment of preeclampsia.Type: ApplicationFiled: September 16, 2009Publication date: July 14, 2011Applicants: University of Pittsburgh-Of the Commonwealth System of Higher Education, University of Florida Research Foundation, Inc.Inventors: Kirk P. Conrad, Arundhathi Jeyabalan, Sandra Anne Founds, William Allen Hogge
-
Publication number: 20110137291Abstract: The present invention provides methods for increasing arterial compliance. The methods generally involve administering to an individual in need thereof an effective amount of relaxin. The present invention further provides methods of increasing arterial compliance in individuals who have Type 1 or Type 2 diabetes. The present invention further provides methods of increasing arterial compliance in perimenopausal, menopausal, and post-menopausal women. The present invention further provides methods of increasing arterial compliance in individuals who have or who are at risk of developing age-associated arterial stiffness.Type: ApplicationFiled: January 6, 2011Publication date: June 9, 2011Inventors: Kirk P. CONRAD, Sanjeev G. Shroff
-
Patent number: 7878978Abstract: The present invention provides methods for increasing arterial compliance. The methods generally involve administering to an individual in need thereof an effective amount of relaxin. The present invention further provides methods of increasing arterial compliance in individuals who have Type 1 or Type 2 diabetes. The present invention further provides methods of increasing arterial compliance in perimenopausal, menopausal, and post-menopausal women. The present invention further provides methods of increasing arterial compliance in individuals who have or who are at risk of developing age-associated arterial stiffness.Type: GrantFiled: March 18, 2005Date of Patent: February 1, 2011Assignee: University of Pittsburgh- Of The Commonwealth System of Higher EducationInventors: Kirk P. Conrad, Sanjeev G. Shroff
-
Publication number: 20040266685Abstract: The invention relates to methods of treating diseases related to vasodilation, generally comprising administering to an individual an effective amount of a pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females, and is therefore useful in treating a wide variety of diseases relating to vasoconstriction.Type: ApplicationFiled: April 5, 2004Publication date: December 30, 2004Inventors: Kirk P. Conrad, Martyn Lewis, Elaine N. Unemori, Xinfan Huang, Carol A. Tozzi
-
Patent number: 6723702Abstract: The invention related to methods of treating disease related to vasoconstriction that is a major factor in hypertensive vascular diseases and vasodilation, generally comprising administering to an individual an effective amount of a pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females, and is useful in treating a wide variety of diseases relating to vasoconstriction.Type: GrantFiled: February 9, 2001Date of Patent: April 20, 2004Assignees: RAS Medical, Inc., The University of Medicine and Dentistry of New Jersey - Robert Wood Johnson Medical School, The University of Pittsburgh - of the Commonwealth System of Higher EducationInventors: Kirk P. Conrad, Martyn Lewis, Elaine N. Unemori, Xinfan Huang, Carol A. Tozzi
-
Publication number: 20020019349Abstract: The invention relates to methods of treating diseases related to vasodilation, generally comprising administering to an individual an effective amount of a pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females, and is therefore useful in treating a wide variety of diseases relating to vasoconstriction.Type: ApplicationFiled: February 9, 2001Publication date: February 14, 2002Inventors: Kirk P. Conrad, Martyn Lewis, Elaine N. Unemori, Xinfan Huang, Carol A. Tozzi